Cytotoxic T-lymphocyte-associated protein 4 in gastric cancer: Prognosis and association with PD-L1 expression

Imagem de Miniatura
Arquivos
art_PEREIRA_Cytotoxic_Tlymphocyteassociated_protein_4_in_gastric_cancer_Prognosis_2021.PDF (1.69 MB)
Citações na Scopus
6
Tipo de produção
article
Data de publicação
2021
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
WILEY
Autores
Citação
JOURNAL OF SURGICAL ONCOLOGY, v.124, n.7, p.1040-1050, 2021
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Background Cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) is one of the most studied immune checkpoint in gastric cancer (GC). However, the prognostic role of CTLA-4 expression in GC is poorly described. This study aimed to evaluate CTLA-4 expression in GC and its impact on survival, including patients treated with standard platinum-based chemotherapy (CMT), and association with PD-L1 expression. Methods All GC patients who underwent D2-gastrectomy were investigated retrospectively. Tumor samples were examined for CTLA-4 and PD-L1 by immunohistochemistry. Tumor-infiltrating inflammatory cells, including CD4 + and CD8 + , were also examined. Results Among the 284 GC patients included, 159 (56%) were CTLA-4 positive and the remaining 125 (44%) were classified as negative. CTLA-4 positive GC was associated with increased inflammatory cell infiltration (p < 0.001), high CD8 + T cells (p = 0.016) and PD-L1 expression (p = 0.026). Considering GC referred for treatment, CTLA-4 negative patients who received CMT had a significant improvement in disease-free survival compared to untreated CLTA-4 negative (p = 0.028). In multivariate analysis, GC positive for both CTLA-4 and PD-L1 had a prognostic impact on survival. Conclusion CTLA-4 positive was associated with PD-L1 expression and a high tumor-infiltrating CD8 + T cells. Accordingly, positivity for both CTLA-4 and PD-L1 was an independent factor associated to better survival in GC patients.
Palavras-chave
chemotherapy, cytotoxic T-lymphocyte associated protein 4, gastric adenocarcinoma, gastric cancer, immune checkpoint
URI
https://observatorio.fm.usp.br/handle/OPI/43850
Referências
  1. Bang YJ, 2012, LANCET, V379, P315, DOI 10.1016/S0140-6736(11)61873-4
  2. Bass AJ, 2014, NATURE, V513, P202, DOI 10.1038/nature13480
  3. Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492
  4. Buchbinder EI, 2016, AM J CLIN ONCOL-CANC, V39, P98, DOI 10.1097/COC.0000000000000239
  5. Callahan MK, 2013, CLIN DERMATOL, V31, P191, DOI 10.1016/j.clindermatol.2012.08.006
  6. CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8
  7. Choi YY, 2019, ANN SURG, V270, P309, DOI 10.1097/SLA.0000000000002803
  8. Choi YY, 2017, J CLIN ONCOL, V35, DOI 10.1200/JCO.2017.35.15_suppl.4022
  9. Cunningham D, 2006, NEW ENGL J MED, V355, P11, DOI 10.1056/NEJMoa055531
  10. Dai CQ, 2016, MOL ONCOL, V10, P1551, DOI 10.1016/j.molonc.2016.09.004
  11. Dias AR, 2016, GASTRIC CANCER, V19, P136, DOI 10.1007/s10120-014-0443-2
  12. Dindo D, 2004, ANN SURG, V240, P205, DOI 10.1097/01.sla.0000133083.54934.ae
  13. Fashoyin-Aje L, 2019, ONCOLOGIST, V24, P103, DOI 10.1634/theoncologist.2018-0221
  14. Figueroa-Protti L, 2019, J ONCOL, V2019, DOI 10.1155/2019/1079710
  15. Gu LH, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0182692
  16. Hu PP, 2017, SCI REP-UK, V7, DOI 10.1038/srep42913
  17. Ji J, 2019, ANN ONCOL, V30
  18. Kawazoe A, 2020, EUR J CANCER, V129, P97, DOI 10.1016/j.ejca.2020.02.002
  19. Kim JW, 2016, GASTRIC CANCER, V19, P42, DOI 10.1007/s10120-014-0440-5
  20. Kim KJ, 2014, HUM PATHOL, V45, P285, DOI 10.1016/j.humpath.2013.09.004
  21. Kim MH, 2019, CANCER RES TREAT, V51, P819, DOI 10.4143/crt.2018.331
  22. Ramos MFKP, 2018, CLINICS, V73, DOI 10.6061/clinics/2018/e543s
  23. Kumagai S, 2020, IMMUNITY, V53, P187, DOI 10.1016/j.immuni.2020.06.016
  24. Lin SJ, 2015, GUT, V64, P1721, DOI 10.1136/gutjnl-2014-308252
  25. Ma J, 2018, DIAGN PATHOL, V13, DOI 10.1186/s13000-018-0766-0
  26. Macdonald JS, 2001, NEW ENGL J MED, V345, P725, DOI 10.1056/NEJMoa010187
  27. Marcus L, 2019, CLIN CANCER RES, V25, P3753, DOI 10.1158/1078-0432.CCR-18-4070
  28. Messager M, 2011, ANN SURG, V254, P684, DOI 10.1097/SLA.0b013e3182352647
  29. Noh SH, 2014, LANCET ONCOL, V15, P1389, DOI 10.1016/S1470-2045(14)70473-5
  30. Pereira MA, 2015, HISTOPATHOLOGY, V66, P388, DOI 10.1111/his.12532
  31. Polom K, 2018, BRIT J SURG, V105, P159, DOI 10.1002/bjs.10663
  32. Ramos MFKP, 2020, J SURG ONCOL, V121, P804, DOI 10.1002/jso.25792
  33. Ramos MFKP, 2020, J GASTROINTEST SURG, V24, P19, DOI 10.1007/s11605-019-04462-z
  34. Rodriquenz MG, 2020, J CLIN MED, V9, DOI 10.3390/jcm9051427
  35. Rotte A, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1259-z
  36. Sano T., 2017, CANC STAGING MANUAL, V17, P203
  37. Smyth EC, 2017, JAMA ONCOL, V3, P1197, DOI 10.1001/jamaoncol.2016.6762
  38. Smyth EC, 2020, J CLIN ONCOL, V38
  39. Tamura T, 2015, ANTICANCER RES, V35, P5369
  40. Yamashita K, 2020, GASTRIC CANCER, V23, P95, DOI 10.1007/s10120-019-00999-9
  41. Zhang XF, 2016, ONCOTARGET, V7, P26670, DOI 10.18632/oncotarget.8476

Coleções
Artigos e Materiais de Revistas Científicas - FM/MGT
Artigos e Materiais de Revistas Científicas - FM/MPT
Artigos e Materiais de Revistas Científicas - HC/ICESP
Artigos e Materiais de Revistas Científicas - HC/ICHC
Artigos e Materiais de Revistas Científicas - LIM/14
Artigos e Materiais de Revistas Científicas - LIM/24
Carregar mais